SF1126 is an investigational drug.
There have been 4 clinical trials for SF1126.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Carcinoma, Hepatocellular, Carcinoma, and Neoplasms, Unknown Primary. The leading clinical trial sponsors are SignalRX Pharmaceuticals, Inc., Semafore Pharmaceuticals, and University of Southern California.
There are thirty-one US patents protecting this investigational drug and three hundred and thirty-seven international patents.